Blood Pressure Drug Recall Now Tops 25,000 Bottles

Inventia Healthcare's second chlorthalidone recall of 2026 brings the total to 25,027 bottles of 25 mg tablets pulled nationwide over failed dissolution testing.

@sharedot

Blood Pressure Drug Recall Now Tops 25,000 Bottles

By @sharedot · · 8 pages

  • Automotive
  • Consumer Recalls
  • Blood Pressure Medication
  • Chlorthalidone
  • FDA Recall

Inventia Healthcare's second chlorthalidone recall of 2026 brings the total to 25,027 bottles of 25 mg tablets pulled nationwide over failed dissolution testing.

What Happened: A Second Recall for the Same Fault

India-based Inventia Healthcare Limited has issued its second voluntary recall of chlorthalidone 25 mg tablets this year after the drug failed dissolution specifications, meaning the tablets do not break down at the correct speed in the body and may not be absorbed properly.

Chlorthalidone is a diuretic, or water pill, that helps the kidneys shed excess salt and water to lower blood pressure.

Why It Matters for Blood Pressure Patients

The surprising element here is not one recall but two for the identical quality failure within four months, both classified by the FDA as Class II — the agency's middle tier, meaning temporary or medically reversible health consequences are possible while serious harm is considered remote.

Because chlorthalidone is a long-term daily medication, patients often refill prescriptions without ever seeing the manufacturer's original bottle, making the lot number rather than the drug name the critical identifier.

BlackDoctor reports that the American Heart Association found high blood pressure affects 62.3% of non-Hispanic Black men and 59.2% of non-Hispanic Black women, with only about 22% of Black adults with hypertension having it under control, which raises the stakes of any disruption to treatment.

The Evidence: Exactly Which Bottles Are Affected

The FDA report identifies the recalled product as Inventia Healthcare Limited's chlorthalidone tablets, USP, 25 mg, sold in 100- and 1,000-tablet bottles with an April 2027 expiration date.

The affected batch codes are RISA24001, RISB24002 and RISA24002, and the recall numbers posted by the FDA are D-0610-2026 and D-0852-2026. The September recall covers NDC 64980-599-01, 100 tablets per bottle, with batch RISA24002 specifically.

The Stakes of a Failed Dissolution Test

Dissolution testing measures whether a tablet releases its active ingredient under defined conditions so the body can absorb it.

The FINANCIAL channel reports that when a batch fails, its performance may be less predictable than required, though the laboratory result does not show how much medicine any individual patient absorbed or whether anyone's blood pressure actually changed.

No injury or death has been documented in connection with the recalled batches. The concern for a blood pressure medicine is that inconsistent drug release could blunt the expected treatment effect, and persistent hypertension raises long-term risks of heart disease, stroke and kidney damage.

The FINANCIAL channel also notes the FDA classified 321 drug recall events covering 755 products in 2025.

What Patients Should Do Now

The FDA advises that for Class II and III recalls consumers can generally continue taking the medicine unless the recalling company gives other instructions, and warns that in some cases stopping a medication may be more harmful than continuing it while a replacement is arranged.

Good Housekeeping reports that FDA classified the September recall as Class II on September 17, and urges anyone holding the recalled tablets to contact a healthcare provider or pharmacist before stopping or changing medication.

Patients should check their bottle for the NDC, batch number and manufacturer name, and pharmacists can verify inventory records if the label lacks the lot. Adverse events can be reported to the FDA's MedWatch program at 1-800-FDA-1088.

What Comes Next

The recall remains ongoing, and the practical next step falls on pharmacies and distributors, who hold records of which manufacturer batches they received and can identify and replace affected stock.

According to The Economic Times, the chlorthalidone action is not the only blood pressure medication problem the FDA has flagged recently — the agency also disclosed that Teva Pharmaceuticals USA and distributor Amerisource Health Services voluntarily recalled more than 580,000 bottles of prazosin capsules over potential nitrosamine impurities, also given Class II classifications.

For patients, the takeaway is to verify the lot with a pharmacist, keep taking prescribed medication until a replacement plan exists, and keep tracking blood pressure readings in the meantime.

Sources

  1. usatoday.com › Blood pressure medication recalled nationwide. See affected drug
  2. news4jax.com › Thousands of bottles of blood pressure medication recalled nationwide
  3. goodhousekeeping.com › FDA Announces New Nationwide Blood Pressure Medication Recall
  4. blackdoctor.com › ALERT: Nationwide Recall of Blood Pressure Medication; 13,000+ Bottles
  5. finchannel.com › Chlorthalidone Recall Covers 13,567 Bottles of Blood Pressure Medication
  6. m.economictimes.com › FDA Chlorthalidone dissolution testing recall: More than 25,000 bottles of blood pressure medication recalled

More on Automotive